ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

14th August, 2026

To,

The Corporate Relationship Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. ***Scrip Code: 539523***	**National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. ***Scrip Symbol: ALKEM***

Sub: Press Release and Analyst Presentation on Q1FY27 Results

Dear Sir(s)/ Madam,

With reference to relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the press release and analyst presentation on Q1FY27 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take a note of the same.

Sincerely,
For **Alkem Laboratories Limited**

MANISH NARANG
Digitally signed by MANISH NARANG
Date: 2026.08.14 13:50:55 +05'30'

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Press Release

Alkem reports 11% revenue growth in Q1FY27

Mumbai, August 14, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors took record of these results at its meeting held in Mumbai today.

Q1FY27 Key Financial Metrics

Total Revenue from Operations	EBITDA / Margin	PAT / Margin
₹37,402 Mn	₹7,661 Mn / 20.5%	₹5,200 Mn / 13.9%
+10.9% YoY Growth	+3.7% YoY Growth	-21.7% YoY Growth

Commenting on the results, Mr. Sandeep Singh, MD of Alkem, said, *"We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging. At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses. We are also investing in R&D, MedTech and Biotech as we build our next phase of growth. Our focus will be to strengthen the core, address the areas that need improvement and build these newer opportunities in a disciplined manner."*

Q1 FY27 Key Financial Highlights

- Total Revenue from Operations was ₹37,402 million, with YoY growth of 10.9%.
    - India sales were ₹24,978 million, YoY growth of 10.3%.
    - International sales were ₹12,223 million, with YoY growth of 16.0%.
- EBITDA at ₹7,661 million, resulted in an EBITDA margin of 20.5%, a growth of 3.7% YoY.
- R&D expenses for Q1 FY27 were ₹1,502 million, or 4.0% of total revenue from operations, vs. ₹1,184 million in Q1 FY26 at 3.5% of total revenue from operations.
- Profit before tax (before exceptional item) was ₹7, 720 million, YoY growth of 1.8%.
- Net Profit (after Non-Controlling interest) was ₹5,200 million, YoY de-growth of 21.7%.

Q1FY27 Operational Highlights

Domestic Business Key Highlights

- The contribution of domestic sales to total sales was 67.1% vs. 68.2% in Q1 FY26.
- According to IQVIA (SSA) data, for Q1 FY27:
    - The Company registered a growth of 13.2% YoY vs Indian Pharmaceutical Market (IPM), which grew by 12.2%, 100 bps outperformance.
    - Acute segment reported growth of 12.3% vs IPM which grew by 10.1%, 220 bps outperformance.

- Chronic segment reported growth of 17.9% vs. IPM which grew by 15.4%, 250 bps outperformance.
- We have outperformed IPM in seven key focused therapies: Anti-infectives grew by ~1.1X; Gastro-intestinal grew by ~1.2X, VMN ~1.4X, Pain ~1.8X, Anti-Diabetic ~1.4X, Respiratory ~1.6X and Derma ~1.6X.

International Business Key Highlights

- US sales were ₹7,439 million, YoY growth of 6.5%.
- US business sales contributed 20.0% to total sales in Q1 FY27 vs. 21.0% in Q1 FY26.
- Non-US sales were ₹4,785 million, YoY growth of 34.5%.
- Non-US business sales contributed 12.9% to total sales in Q1 FY27 vs. 10.8% in Q1 FY26.
- During Q1 FY27, for the US market, the Company received 05 ANDAs approvals (including 01 tentative approval).

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Apr-26	Official Action Indicated (OAI) in Aug 2026.
Taloja R&D (India)	Bioequivalence Centre	Apr-26	No observation received.
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	EIR Received in Oct 2025

About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50+ years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 20 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, Europe and several other Asian countries. "Inspiring Healthier Lives" is at the core of the organization's values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, and Facebook.

Contact

Investors:
Purvi Shah / Dishant Doshi
+91 84337 00890 / 99201 56882
purvi.shah@alkem.com / dishant.doshi@alkem.com

Media:
Isha Trivedi / Richa Sinari
+91 98925 90003 / 98201 84988
alkemcorpcomm@alkem.com

ALKEM
Inspiring Healthier Lives

ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

Invite for Q1FY27 Conference Call at 4.30 pm IST, August 14, 2026

Mumbai, July 27, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Friday, August 14, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q1FY27 financial results. The call will follow the announcement of the Company's Q1FY27 financial results on Friday, August 14, 2026.

Alkem Laboratories Ltd. will be represented on the call by:

Mr. Sandeep Singh - MD
Mr. Nitin Agrawal – CFO

Motilal Oswal Securities Ltd will host the call.

Details of the conference call are as follows

Time	4:30 pm IST (GMT + 5:30) on Friday, August 14, 2026.

Dial in Details

India	+91 22 6280 1149 / +91 22 7115 8050

International Toll-Free

USA	1 866 746 2133	**UK**	0 808 101 1573
Singapore	800 101 2045	**Hong Kong**	800 964 448

Express Join with Diamond Pass

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6179880&linkSecurityString=34f8c9ec58

You are requested to dial in 10 minutes ahead of the scheduled start time.

Purvi Shah / Isha Trivedi
Investor Relations / Media
Alkem Laboratories Ltd.
Mobile: +91 84337 00890 / 98925 90003
Tel.: +91 22 3982 9999 Ext: 9447
E-mail:purvi.shah@alkem.com/
isha.trivedi@alkem.com

Tushar Manudhane
Institutional Research Analyst - Healthcare
Motilal Oswal Securities Ltd.
Tel.: +91 22 6129 1536 / +91 82911 38039
E-mail: Tushar.Manudhane@motilaloswal.com

ALKEM
Inspiring Healthier Lives

Alkem Laboratories Ltd.

Q1 FY27 Results Presentation

14th August 2026

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

CONTENTS

Q1 FY27 Performance at Glance

Total Revenue from Operations

₹37,402 Mn

+10.9% YoY Growth

EBITDA / Margin

₹7,661 Mn / 20.5%

+3.7% YoY Growth

PAT[1] / Margin

₹5,200 Mn / 13.9%

-21.7% YoY Growth

Geographic-wise Break-Up

Domestic Business

67.1%

International Business

32.9%

Salient Numbers

₹57.64 Bn
Net Cash as of 30th June 2026

₹1,502 Mn
R&D spend for Q1 FY27

100 bps
Outperformance in the domestic market vs. IPM

4.0%
R&D spend as % of sales during the quarter

1. PAT: Profit after Non Controlling Interest

Q1 FY27 – P&L Highlights

Particulars	Q1FY27	Q1FY26	YoY growth	Q4FY26	QoQ growth
Revenue from Operations	37,402	33,711	10.9%	36,033	3.8%
Gross Profit	25,389	22,000	15.4%	23,555	7.8%
Gross Profit Margin	67.9%	65.3%		65.4%	
EBITDA	7,661	7,391	3.7%	5,174	48.1%
EBITDA Margin	20.5%	21.9%		14.4%	
PBT (before exceptional item)	7,720	7,581	1.8%	5,578	38.4%
Exceptional item	-	129		(1,350)	
PBT (after exceptional item)	7,720	7,710	0.1%	4,229	82.6%
PAT (after Non-Controlling Interest)	5,200	6,643	-21.7%	2,365	119.9%
PAT Margin	13.9%	19.7%		6.6%	
EPS (₹ / share)	43.5	55.6	-21.7%	19.8	119.9%

CONTENTS

Domestic Business Performance

Q1 FY27 sales of ₹24,978 Mn (10.3% YoY growth)



- Domestic business revenue grew by 10.3% YoY to ₹24,978 Mn from ₹ 22,650 Mn during the same period last year.
- Domestic revenue contributed 67.1% to total sales in Q1 FY27 vs. 68.2% in Q1 FY26.
- According to IQVIA (SSA) data, for Q1 FY27:
  - The Company registered a growth of 13.2% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 12.2%.
  - We've grown faster than the market in seven of IPM's key therapy areas.

Alkem has delivered a strong performance in Q1 FY27, outpacing the market growth in key focus therapies

Outpaced the market by 100 bps, delivering 13.2% growth vs. 12.2% for IPM



Outperformance in 7 of the key IPM focus therapies

Therapy Class	Growth YoY %	Market share %		IPM Rank – Value	
Anti Infectives	7.9% / 6.9%	13.3%	+0.1%	1	
Gastro Intestinal	12.2% / 10.2%	7.9%	+0.1%	4	
VMN	21.4% / 15.1%	6.8%	+0.4%	2	
Pain / Analgesics	20.2% / 11.5%	5.6%	+0.4%	3	
Anti Diabetic	21.1% / 15.5%	2.3%	+0.1%	13	+1
Neuro / CNS	8.7% / 12.0%	2.4%	-0.1%	8	
Respiratory	16.8% / 10.5%	1.5%	+0.1%	14	
Derma	16.5% / 10.3%	1.6%	+0.1%	19	

15+ years of unmatched leadership in the Anti-Infectives therapy

Source: Market data as per IQVIA SSA Qtr. Jun'26

US Business Performance

Q1 FY27 US Business sales of ₹7,439 Mn (6.5% YoY growth)



- US business revenue grew by 6.5% YoY to ₹7,439 Mn from ₹ 6,982 Mn during the same period last year.
- US revenue contributed 20.0% to total sales in Q1 FY27.
- During the Q1 FY27, the Company received 05 ANDAs approvals (including 01 tentative approvals).

US Market Filing and approvals status



As of June 30, 2026, the Company has **filed 192 ANDAs, 2 NDAs and 1 BLA** and has **received 170 ANDAs approvals** (including 18 tentative approvals) **and 2 NDAs approvals.**

Non-US Business Performance

Q1 FY27 sales of ₹4,785 Mn (34.5% YoY growth)

Sales (in ₹ Mn)



- Non-US business revenue grew by 34.5% YoY to ₹4,785 Mn from ₹ 3,556 Mn during the same period last year.
- Non-US revenue contributed 12.9% to total sales in Q1 FY27.
- The Non-US business growth was driven by double-digit growth across key markets.

Shareholding Pattern as on June 30, 2026



BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	665,894
Free Float MCap (Rs in Mn)	334,944
Industry	Pharmaceuticals

**Share Price - Rs 5,570 from NSE as of 30th June 2026*

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

CONTENTS

Alkem Laboratories at Glance (FY26)

Market Leadership	**#3** Rank in Prescriptions[1]	**#6** Rank by value in IPM[2]	**Leading Player** In the Trade Generics segment	**Top 3** Player in 4 out of top 7 largest IPM's TAs[2]
Scale	**₹1,47,123 Mn** Total Revenue[3]	**67.8%** Domestic Revenue	**17** Brand families worth ₹1000 Mn+[2]	**14,500+** Field force[4]
Profitability	**65.4%** Gross Profit Margin	**20.4%** EBITDA Margin	**15.6%** PAT Margin	**29.6%** ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Feb'26; 2. Market data as per IQVIA SSA MAT Mar'26; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31st March 2026

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

ALKEM
Inspiring Healthier Lives

#2 'PAN'
Biggest Brand family in the IPM

15 Brands
in the IPM Top 300 ranks

36 Brands
Among the Top 3 ranks in their CVM[1] (Brands > ₹250 Mn)

Building large brand families defines our identity…

Brand Families	MAT Mar'21	MAT Mar'26	CAGR (5 Yrs.)
> ₹10 Bn	0	1	15.2%
> ₹5 Bn	1	1	12.4%
> ₹1.5 Bn	5	12	12.4%
> ₹500 Mn	15	17	11.2%

Brand family > ₹5 Bn

PAN CLAVAM

Brand family > ₹1.5 Bn

A TO Z NS, XONE, TAXIM-O, Uprise®-D_3, Gemcal, PIPZO®, SUMOL, DAPANORM, Swich, TRAXOL, CHERi, TAXIM

Source: Market data as per IQVIA SSA MAT Mar'26; 1. CVM is Covered Market

50+ years of Alkem journey – a snapshot.

ALKEM
Inspiring Healthier Lives

Alkem & key subsidiaries

ALKEM Inspiring Healthier Lives

ENZENE Biosciences Ltd. Passion. Innovation. Life

Indchemie HEALTH SPECIALITIES PVT. LTD.

CACHET

ASCEND Laboratories, LLC

ASCEND Laboratories, SpA.

Pharmacor

Alkem MedTech Innovative. Affordable. Accessible

1973

Inception of Alkem Laboratories Limited

1978

Established the first plant at Taloja, Mumbai

2003

First R&D facility established at Taloja

2006

Taxim became India's first anti-infective drug to surpass annual sales figure of ₹ 1 billion in the domestic market

TAXIM

2007

Filed the first ANDA in the US for the drug Amlodipine

2009

Received the first ANDA approval in the US for the drug Amlodipine.
Acquired Pharmacor Pty. Ltd., a generic pharmaceutical Company in Australia

Pharmacor

2010

Acquired Ascend Laboratories, a pharmaceutical Company in the US

ASCEND Laboratories, LLC

2011

Acquired Enzene Biosciences, a Company engaged in the development of biosimilars in India

ENZENE Biosciences Ltd.

2012

Acquired an API manufacturing facility in the US

2014

Clavam surpassed ₹ 2 billion domestic sales milestone

CLAVAM

2015

Successfully completed Initial Public Offering (IPO)

2018

Revenue from the US market crossed US$ 200 million in annual sales

2019

Crossed the revenue milestone of US$ 1 billion

2020

Started a new biologic/ biosimilar manufacturing facility in Pune

TGx business delivered 10+ billion topline

2021

First product launched from Enzene Biosciences in India

Company forayed in the respiratory segment in India with the launch of Pulmocare division

2022

Awarded as "Pharma Company of the Year" in ET India Pharma World Awards 2023

PAN franchise crossed ₹ 10 billion sales milestone

Clavam crossed ₹ 6 billion sales milestone

PAN40 CLAVAM

2023

50 years of Alkem

ALKEM 50 YEARS OF EXCELLENCE

2024 - 26

2024–25 – Entry into MedTech through Advita Ortho (erstwhile Exactech) licensing agreement.

Included in the MSCI India Index.

2025–26 – Adroit & Bombay Ortho Acquisition completed. Carve out of Trade Generics business into subsidiary "Alkem Wellness".

Source: Internal data

THANK YOU

For any queries, contact:

Purvi Shah / Dishant Doshi

Mobile: +91 84337 00890 / 99201 56882

E-mail: purvi.shah@alkem.com / dishant.doshi@alkem.com